Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/490413 http://scihub22266oqcxt.onion/10.1155/2015/490413 C4657067!4657067 !26640759     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26640759 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Anal+Cell+Pathol+(Amst) 2015 ; 2015 (ä): 490413 Nephropedia Template TP {{tp|p=26640759 |t=2015. C1q Nephropathy: The Unique Underrecognized Pathological Entity |pdf=|usr=}}{{26640759 }} gab.com Text C1q Nephropathy: The Unique Underrecognized Pathological Entity JO: Anal Cell Pathol (Amst) http://www.kidney.de/pget.php?&tw=1&pmid=26640759 #FOAvip C1q nephropathy is a rare glomerular disease with characteristic mesangial C1q deposition noted on immunofluorescence microscopy. It is histologically defined and poorly understood. Light microscopic features are heterogeneous and comprise minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and proliferative glomerulonephritis. Clinical presentation is also diverse, and ranges from asymptomatic hematuria or proteinuria to frank nephritic or nephrotic syndrome in both children and adults. Hypertension and renal insufficiency at the time of diagnosis are common findings. Optimal treatment is not clear and is usually guided by the underlying light microscopic lesion. Corticosteroids are the mainstay of treatment, with immunosuppressive agents reserved for steroid resistant cases. The presence of nephrotic syndrome and FSGS appear to predict adverse outcomes as opposed to favorable outcomes in those with MCD. Further research is needed to establish C1q nephropathy as a universally recognized distinct clinical entity. In this paper, we discuss the current understanding of pathogenesis, histopathology, clinical features, therapeutic options, and outcomes of C1q nephropathy. Twit Text FOAVip C1q Nephropathy: The Unique Underrecognized Pathological Entity ????Anal Cell Pathol (Amst) http://www.kidney.de/pget.php?&tw=1&pmid=26640759 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26640759 #FOAvip English Wikipedia <ref>{{Cite pmid|26640759 }}</ref> C1q Nephropathy: The Unique Underrecognized Pathological Entity #MMPMID26640759 Devasahayam J ; Erode-Singaravelu G ; Bhat Z ; Oliver T ; Chandran A ; Zeng X ; Dakshinesh P ; Pillai U Anal Cell Pathol (Amst) 2015[]; 2015 (ä): 490413 PMID26640759 show ga C1q nephropathy is a rare glomerular disease with characteristic mesangial C1q deposition noted on immunofluorescence microscopy. It is histologically defined and poorly understood. Light microscopic features are heterogeneous and comprise minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and proliferative glomerulonephritis. Clinical presentation is also diverse, and ranges from asymptomatic hematuria or proteinuria to frank nephritic or nephrotic syndrome in both children and adults. Hypertension and renal insufficiency at the time of diagnosis are common findings. Optimal treatment is not clear and is usually guided by the underlying light microscopic lesion. Corticosteroids are the mainstay of treatment, with immunosuppressive agents reserved for steroid resistant cases. The presence of nephrotic syndrome and FSGS appear to predict adverse outcomes as opposed to favorable outcomes in those with MCD. Further research is needed to establish C1q nephropathy as a universally recognized distinct clinical entity. In this paper, we discuss the current understanding of pathogenesis, histopathology, clinical features, therapeutic options, and outcomes of C1q nephropathy. |Complement Activation/immunology [MESH] |Complement C1q/*immunology [MESH] |Humans [MESH] |Kidney Diseases/etiology/*pathology/therapy [MESH] |Kidney/pathology/ultrastructure [MESH]C1q Nephropathy: The Unique Underrecognized Pathological Entity (epmc).pdf DeepDyve Pubget Overpricing